|
1）Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum. 2006; 36: 71-81
|
|
|
|
2）三森経世. 抗核抗体研究の進歩─自己抗体が認識する核および細胞質蛋白の構造と機能─. リウマチ. 1992; 32: 366-78
|
|
|
|
|
3）Peng SL, Madaio MP, Hayday AC, et al. Propagation and regulation of systemic autoimmunity by γδT cells. J Immunol. 1996; 157: 5689- 98
|
|
|
|
|
|
4）Peng SL, Madaio MP, Hughes DPM, et al. Murine lupus in the absence of αβ T cells. J Immunol. 1996; 156: 4041-9
|
|
|
|
|
|
5）Peng SL, Fatenejad S, Craft J. Induction of nonpathogenic, humoral autoimmunity in lupus-prone mice by a class II-restricted, transgenic αβ T cell. Separation of autoantigen-specific and-nonspecific help. J Immunol. 1996; 157: 5225-30
|
|
|
|
|
|
6）Ma J, Xu J, Madaio MP, et al. Autoimmune lpr/lpr mice deficient in CD40 ligand. Spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol. 1996; 157: 417- 26
|
|
|
|
|
|
7）Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black x New Zealand White mice. Response correlates with the absence of an anti-antibody response. J Immunol. 1996; 157: 3159-64
|
|
|
|
|
|
8）Harn BH. Antibodies to DNA. N Engl J Med. 1998; 338: 1359-68
|
|
|
|
|
|
9）Christensen SR, Kashgarian M, Alexopoulou L, et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 2005; 202: 321-31
|
|
|
|
|
|
10）Anders HJ, Vielhauer V, Eis V, et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 2004; 18: 534-6
|
|
|
|
|
|
11）Chan OTM, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999; 189: 1639-47
|
|
|
|
|
|
12）Izui S, Kelly VE, Masuda K, et al. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol. 1984; 133: 227-33
|
|
|
|
|
|
13）Bijl N, Dijstelbloem HM, Oost WW, et al. IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology. 2002; 41: 62-7
|
|
|
|
|
|
14）Ben NA, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature. 1981; 292: 60-1
|
|
|
|
|
|
15）Medaer R, Stinissen P, Truyen L, et al. Depletion of myelin-basic-protein autoreactive T cells by T cell-vaccination: pilot trial in multiple sclerosis. Lancet. 1995; 346: 807-8
|
|
|
|
|
|
16）Van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol. 2003; 131: 155-68
|
|
|
|
|
|
17）Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA. 2004; 101: 14599-606
|
|
|
|
|
|
18）Hong J, Zang YCQ, Nie H, et al. CD4＋ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci USA. 2006; 103: 5024-9
|
|
|
|
|
|
19）Mimran A, Mor F, Carmi P, et al. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. J Clin Invest. 2004; 113: 923-32
|
|
|
|
|
|
20）Cohen IR, Quintana FJ, Mimran A. Tregs in T cell vaccination: exploring the regulation of regulation. J Clin Invest. 2004; 114: 1227-32
|
|
|
|
|
|
21）De Alboran IM, Gutierrez JC, Gonzalo JA, et al. lpr T cells vaccinate agaist lupus in MRL/lpr mice. Eur J Immunol. 1992; 22: 1089-93
|
|
|
|
|
|
22）Ben-Yuhuda A, Bar-Tana R, Livoff A, et al. Lymph node cell vaccination against the lupus syndrome of MRL/lpr/lpr mice. Lupus. 1996; 5: 232-6
|
|
|
|
|
|
23）Li Z-G, Mu R, Dai Z-P, et al. T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus. 2005; 14: 854-9
|
|
|
|
|
|
24）Singh RR. The potential use of peptides and vaccination to treat systemic lupus erythematosus. Curr opin Rheumatol. 2000; 12: 399-406
|
|
|
|
|
|
25）Monneaux F, Muller S. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun Rev. 2004; 3: 16-24
|
|
|
|
|
|
26）Harn BH, Singh RR, Wong WK, et al. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum. 2001; 44: 432-41
|
|
|
|
|
|
27）Suen JL, Chuang YH, Tsai BY, et al. Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum. 2004; 50: 3250-9
|
|
|
|
|
|
28）Amital H, Heilweil M, Ulmansky R, et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J Immunol. 2005; 175: 5516-23
|
|
|
|
|
|
29）Shatrabi A, Zinger H, Zborowsky M, et al. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4＋CD25＋ cells and TGF-β. Proc Natl Acad Sci USA. 2006; 103: 8810-5
|
|
|
|
|